|
1.
|
|
|
2.
|
|
10 p, 903.6 KB |
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy
/
Perl, Alexander E. (University of Pennsylvania) ;
Larson, Richard A (University of Chicago) ;
Podoltsev, Nikolai A. (Yale School of Medicine) ;
Strickland, Stephen (Vanderbilt-Ingram Cancer Center) ;
Wang, Eunice S. (Roswell Park Comprehensive Cancer Center) ;
Atallah, Ehab (Medical College of Wisconsin) ;
Schiller, Gary J. (David Geffen School of Medicine at UCLA) ;
Martinelli, Giovanni (IRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori "Dino Amadori" IRST S.r.l) ;
Neubauer, Andreas (Universitätsklinikum Giessen und Marburg GmbH) ;
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ;
Montesinos, Pau (Hospital Universitari i Politècnic La Fe (València)) ;
Recher, Christian (Centre Hospitalier Universitaire de Toulouse. Institut Universitaire du Cancer de Toulouse Oncopole. Université de Toulouse 3 Paul Sabatier) ;
Yoon, Sung-Soo (Seoul National University Hospital) ;
Maeda, Yoshinobu (Okayama University Hospital) ;
Hosono, Naoko (University of Fukui) ;
Onozawa, Masahiro (Hokkaido University) ;
Kato, Takayrasu (Department of Hematology. University of Tsukuba) ;
Kim, Hee-Je (Catholic Hematology Hospital. College of Medicine. The Catholic University of Korea) ;
Hasabou, Nahla (Astellas Pharma US. Inc.) ;
Nuthethi, Rishita (Astellas Pharma US. Inc.) ;
Tiu, Ramon (Astellas Pharma US. Inc.) ;
Levis, Mark J. (Sidney Kimmel Comprehensive Cancer Center. Johns Hopkins University)
The fms-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib improved the survival of patients with relapsed or refractory (R/R) FLT3-mutated acute myelogenous leukemia (AML) in the phase 3 ADMIRAL trial. [...]
2023 -  10.1016/j.jtct.2022.12.006
Transplantation and Cellular Therapy, Vol. 29 Núm. 4 (april 2023) , p. 265.e1-265.e10
|
|
|
3.
|
|
11 p, 673.6 KB |
DLST mutations in pheochromocytoma and paraganglioma cause proteome hyposuccinylation and metabolic remodeling
/
Mellid, Sara (Hereditary Endocrine Cancer Group. Spanish National Cancer Research Centre) ;
García, Fernando (Proteomics Unit. Spanish National Cancer Research Centre) ;
Leandro-García, Luís Javier (Hereditary Endocrine Cancer Group. Spanish National Cancer Research Centre) ;
Díaz-Talavera, Alberto (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Martínez-Montes, Ángel Mario (Hereditary Endocrine Cancer Group. Spanish National Cancer Research Centre) ;
Gil, Eduardo (Hereditary Endocrine Cancer Group. Spanish National Cancer Research Centre) ;
Calsina, Bruna (Hereditary Endocrine Cancer Group. Spanish National Cancer Research Centre) ;
Monteagudo, María (Hereditary Endocrine Cancer Group. Spanish National Cancer Research Centre) ;
Letón, Rocío (Hereditary Endocrine Cancer Group. Spanish National Cancer Research Centre) ;
Roldán-Romero, Juan María (Hereditary Endocrine Cancer Group. Spanish National Cancer Research Centre) ;
Santos, María (Hereditary Endocrine Cancer Group. Spanish National Cancer Research Centre) ;
Lanillos, Javier (Hereditary Endocrine Cancer Group. Spanish National Cancer Research Centre) ;
Valdivia, Carlos (Hereditary Endocrine Cancer Group. Spanish National Cancer Research Centre) ;
Martínez-Puente, Natalia (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
de Nicolás-Hernández, Javier (Hereditary Endocrine Cancer Group. Spanish National Cancer Research Centre) ;
Jiménez,Scherezade (Monoclonal Antibodies Core Unit. Spanish National Cancer Research Centre) ;
Pérez-Martínez, Manuel (Confocal Microscopy Core Unit. Spanish National Cancer Research Centre) ;
Honrado, Emiliano (Anatomical Pathology Service. Hospital of León) ;
Coloma, Javier (Structural Biology Programme. Spanish National Cancer Research Centre) ;
Cerezo, Ana (CNIO-Lilly Cell Signalling and Immunometabolism Section. Spanish National Cancer Research Centre) ;
Santiveri, Clara María (Spectroscopy and Nuclear Magnetic Resonance Unit. Spanish National Cancer Research Centre) ;
Esteller, M (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Campos-Olivas, Ramón (Spectroscopy and Nuclear Magnetic Resonance Unit. Spanish National Cancer Research Centre) ;
Caleiras, Eduardo (Histopathology Core Unit. Spanish National Cancer Research Centre) ;
Montero-Conde, Cristina (Hereditary Endocrine Cancer Group. Spanish National Cancer Research Centre) ;
Rodríguez-Antona, Cristina (Hereditary Endocrine Cancer Group. Spanish National Cancer Research Centre) ;
Muñoz, Javier (Ikerbasque. Basque Foundation for Science) ;
Robledo, Mercedes (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Cascón, Alberto (Centro de Investigación Biomédica en Red de Enfermedades Raras)
2023 - 10.1002/cac2.12427
Cancer Communications, Vol. 43 Núm. 7 (july 2023) , p. 838-843
|
|
|
4.
|
|
7 p, 660.3 KB |
Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia : the importance of characterizing ABL1 mutations in cerebrospinal fluid
/
Sanchez, R. (Hospital 12 de Octubre (Madrid)) ;
Ayala, Rosa (Hospital 12 de Octubre (Madrid)) ;
Alonso, R.A. (Hospital 12 de Octubre (Madrid)) ;
Martínez, M.P. (Hospital 12 de Octubre (Madrid)) ;
Ribera, Jordi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
García, Olga (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sanchez-Pina, J. (Hospital 12 de Octubre (Madrid)) ;
Mercadal, S. (ICO-Hospital Duran i Reynals (Bellvitge)) ;
Montesinos, P. (Hospital Universitari i Politècnic La Fe de València) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Barba, Pere (Hospital Universitari Vall d'Hebron) ;
González-Campos, J. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Barrios, M. (Hospital Regional Universitario Carlos Haya (Málaga)) ;
Lavilla, E. (Hospital Universitario Lucus Augusti (Lugo)) ;
Gil, C. (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Bernal, T. (Hospital Universitario Central de Asturias) ;
Escoda, L. (Hospital Universitari Joan XXIII de Tarragona) ;
Abella Monreal, Eugenia (Hospital del Mar (Barcelona, Catalunya)) ;
Amigo, María-Luz (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Moreno, M.J. (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Bravo, P. (Hospital de Fuenlabrada) ;
Guàrdia, R. (Hospital Universitari de Girona Doctor Josep Trueta) ;
Hernández-Rivas, J.M. (Hospital Universitario de Salamanca) ;
García-Guiñón, A. (Hospital Universitari Arnau de Vilanova) ;
Piernas, Sonia (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Ribera, José Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez-López, J. (Hospital 12 de Octubre (Madrid)) ;
Universitat Autònoma de Barcelona
We investigated the frequency, predictors, and evolution of acute lymphoblastic leukemia (ALL) in patients with CNS relapse and introduced a novel method for studying BCR-ABL1 protein variants in cDNA from bone marrow (BM) and cerebrospinal fluid (CSF) blast cells. [...]
2017 - 10.1007/s00277-017-3002-1
Annals of Hematology, Vol. 96 Núm. 7 (january 2017) , p. 1069-1075
|
|
|
5.
|
|
11 p, 1.3 MB |
Detection of oncogenic and clinically actionable mutations in cancer genomes critically depends on variant calling tools
/
García-Prieto, Carlos A (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Martínez Jiménez, Francisco (Institute for Research in Biomedicine (IRB Barcelona)) ;
Valencia, Alfonso (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Porta-Pardo, Eduard (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Motivation: The analysis of cancer genomes provides fundamental information about its etiology, the processes driving cell transformation or potential treatments. While researchers and clinicians are often only interested in the identification of oncogenic mutations, actionable variants or mutational signatures, the first crucial step in the analysis of any tumor genome is the identification of somatic variants in cancer cells (i. [...]
2022 - 10.1093/bioinformatics/btac306
Bioinformatics, Vol. 38 Núm. 12 (15 2022) , p. 3181-3191
|
|
|
6.
|
|
9 p, 204.1 KB |
Pseudoprogression as an adverse event of glioblastoma therapy
/
Balañá, Carmen (Institut Catala Oncologia (ICO)) ;
Capellades, Jaume (Hospital del Mar (Barcelona, Catalunya)) ;
Pineda, Estela (Hospital Clínic i Provincial de Barcelona) ;
Estival, Anna (Institut Catala Oncologia (ICO)) ;
Puig, Josep (Hospital Universitari de Girona Doctor Josep Trueta) ;
Domenech, Sira (Institut Diagnòstic per la Imatge (IDI)) ;
Verger, Eugenia (Hospital Clínic i Provincial de Barcelona) ;
Pujol, Teresa (Hospital Clínic i Provincial de Barcelona) ;
Martinez-García, Maria (Hospital del Mar (Barcelona, Catalunya)) ;
Oleaga, Laura (Hospital Clínic i Provincial de Barcelona) ;
Velarde, Josep Maria (Institut Catala Oncologia (ICO)) ;
Mesia, Carlos (Hospital Universitari de Bellvitge) ;
Fuentes, Rafael (Institut Catala Oncologia (ICO)) ;
Marruecos, Jordi (Institut Catala Oncologia (ICO)) ;
Del Barco, Sonia (Institut Catala Oncologia (ICO)) ;
Villà, Salvador (Institut Catala Oncologia (ICO)) ;
Carrato, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Gallego Rubio, Oscar (Institut d'Investigació Biomèdica Sant Pau) ;
Gil-Gil, Miguel (Hospital Universitari de Bellvitge) ;
Craven-Bartle, Jordi (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Alameda, Francesc (Hospital del Mar (Barcelona, Catalunya)) ;
Universitat Autònoma de Barcelona
We explored predictive factors of pseudoprogression (PsP) and its impact on prognosis in a retrospective series of uniformly treated glioblastoma patients. Patients were classified as having PsP, early progression (eP) or neither (nP). [...]
2017 - 10.1002/cam4.1242
Cancer Medicine, Vol. 6 Núm. 12 (december 2017) , p. 2858-2866
|
|
|
7.
|
|
103 p, 12.2 MB |
Feline Infectious Peritonitis : European Advisory Board on Cat Diseases Guidelines
/
Tasker, S. (Linnaeus Veterinary Limited) ;
Addie, Diane D (Independent Researcher) ;
Egberink, Herman (University of Utrecht. Department of Biomolecular Health Sciences) ;
Hofmann-Lehmann, Regina (University of Zurich. Department of Clinical Diagnostics and Services) ;
Hosie, Margaret J (University of Glasgow Centre for Virus Research) ;
Truyen, U. (University of Leipzig. Institute of Animal Hygiene and Veterinary Public Health) ;
Belák, Sándor (Swedish University of Agricultural Sciences. Department of Biomedical Sciences and Veterinary Public Health) ;
Boucraut-Baralon, Corine (Scanelis Veterinary Test Laboratory) ;
Frymus, Tadeusz (Warsaw University of Life Sciences. Department of Small Animal Diseases with Clinic) ;
Lloret Roca, Albert (Universitat Autònoma de Barcelona. Hospital Clínic Veterinari) ;
Marsilio, Fulvio (Università Degli Studi di Teramo. Faculty of Veterinary Medicine) ;
Pennisi, Maria Grazia (Università di Messina. Dipartimento di Scienze Veterinarie) ;
Thiry, Etienne (Liège University. Department of Infectious and Parasitic Diseases) ;
Möstl, K. (University of Veterinary Medicine. Department for Pathobiology.) ;
Hartmann, Katrin (LMU Small Animal Clinic. Centre for Clinical Veterinary Medicine)
Feline coronavirus (FCoV) is a ubiquitous RNA virus of cats, which is transmitted faeco-orally. In these guidelines, the European Advisory Board on Cat Diseases (ABCD) presents a comprehensive review of feline infectious peritonitis (FIP). [...]
2023 - 10.3390/v15091847
Viruses, Vol. 15 Núm. 9 (september 2023) , p. 1847
|
|
|
8.
|
|
10 p, 666.8 KB |
Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain
/
Arriola, Edurne (Hospital del Mar (Barcelona, Catalunya)) ;
García Gómez, Ramón (Hospital General Universitario Gregorio Marañón) ;
Diz Taín, Pilar (Hospital Universitario de León) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Martínez Aguillo, Maite (Complejo Hospitalario de Navarra) ;
Valdivia, Javier (Hospital Universitario Virgen de las Nieves (Granada)) ;
Paredes, Alfredo (Hospital de Donostia (Sant Sebastià, País Basc)) ;
Sánchez-Torres, José Miguel (Hospital Universitario de la Princesa (Madrid)) ;
Peralta Muñoz, Sergio (Hospital Universitari Sant Joan de Reus (Tarragona)) ;
Barneto Aranda, Isidoro (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ;
Gutierrez, Vanesa (Hospital Regional Universitario Carlos Haya (Málaga)) ;
Andrade Santiago, Jesús Manuel (Hospital Virgen de la Salud (Toledo)) ;
Aparisi, Francisco (Hospital Virgen de los Lirios) ;
Isla, Dolores (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Ponce, Santiago (Hospital 12 de Octubre (Madrid)) ;
Vicente Baz, David (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Artal, Ángel (Hospital Universitario Miguel Servet (Saragossa)) ;
Amador, Mariluz (AstraZeneca) ;
Provencio, Mariano (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Universitat Autònoma de Barcelona
Although the benefit of first-line epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) over chemotherapy has been demonstrated in several clinical trials, data from clinical practice is lacking and the optimal EGFR TKI to be used remains unclear. [...]
2018 - 10.1186/s12885-018-4004-7
BMC Cancer, Vol. 18 Núm. 1 (30 2018) , p. 106
|
|
|
9.
|
|
11 p, 5.0 MB |
Fibroblast activation and abnormal extracellular matrix remodelling as common hallmarks in three cancer-prone genodermatoses
/
Chacón-Solano, Esteban (Regenerative Medicine and Tissue Engineering Group. Fundación Jiménez Díaz (IIS-FJD)) ;
León Canseco, Carlos (Regenerative Medicine and Tissue Engineering Group. Fundación Jiménez Díaz (IIS-FJD)) ;
Díaz, F. (Regenerative Medicine and Tissue Engineering Group. Fundación Jiménez Díaz (IIS-FJD)) ;
García-García, Francisco (Bioinformatics and Biostatistics Unit. Centro de Investigación Príncipe Felipe (CIPF)) ;
García, M. (Epithelial Biomedicine Division. CIEMAT-CIBERER (U714)) ;
Escámez Toledano, María José (Epithelial Biomedicine Division. CIEMAT-CIBERER (U714)) ;
Guerrero-Aspizua, Sara (Epithelial Biomedicine Division. CIEMAT-CIBERER (U714)) ;
Conti, C.J. (Regenerative Medicine and Tissue Engineering Group. Fundación Jiménez Díaz (IIS-FJD)) ;
Mencía, None (Regenerative Medicine and Tissue Engineering Group. Fundación Jiménez Díaz (IIS-FJD)) ;
Martínez-Santamaría, L. (Regenerative Medicine and Tissue Engineering Group. Fundación Jiménez Díaz (IIS-FJD)) ;
Llames, S. (Tissue Engineering Unit. Centro Comunitario Sangre y Tejidos (CCST)) ;
Pévida, M. (Tissue Engineering Unit. Centro Comunitario Sangre y Tejidos (CCST)) ;
Carbonell-Caballero, J. (Department of Computational Genomics. Centro de Investigación Príncipe Felipe (CIPF)) ;
Puig-Butille, Joan Anton (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Maseda, R. (Department of Pediatric Dermatology. La Paz Hospital) ;
Puig, Susana (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
de Lucas, R. (Department of Pediatric Dermatology. La Paz Hospital) ;
Baselga Torres, Eulàlia (Institut d'Investigació Biomèdica Sant Pau) ;
Larcher, F. (Epithelial Biomedicine Division. CIEMAT-CIBERER (U714)) ;
Dopazo, J. (Bioinformatics in Rare Diseases (BiER-U715). CIBERER. FPS. Hospital Virgen del Rocío) ;
del Río, M. (Epithelial Biomedicine Division. CIEMAT-CIBERER (U714))
Background: Recessive dystrophic epidermolysis bullosa (RDEB), Kindler syndrome (KS) and xeroderma pigmentosum complementation group C (XPC) are three cancer-prone genodermatoses whose causal genetic mutations cannot fully explain, on their own, the array of associated phenotypic manifestations. [...]
2019 - 10.1111/bjd.17698
British journal of dermatology, Vol. 181 Núm. 3 (january 2019) , p. 512-522
|
|
|
10.
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
